-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axelopran in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axelopran in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axelopran in Recurrent Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexmedetomidine Hydrochloride in Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dexmedetomidine Hydrochloride in Pain Drug Details: Dexmedetomidine Hydrochloride (Precedex, Dexdor, Xamdex) is a sedative agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexmedetomidine Hydrochloride in Cancer Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dexmedetomidine Hydrochloride in Cancer Pain Drug Details: Dexmedetomidine Hydrochloride (Precedex, Dexdor, Xamdex) is a sedative...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Non-Small Cell Lung Cancer Drug Details: Ceralasertib is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin in Sickle Cell Disease Drug Details: Rifaximin (Xifaxan / Normix...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FX-5A in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FX-5A in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FX-5A in AtherosclerosisDrug Details:FX-5A is under development for the treatment of atherosclerosis and heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPH-5301 in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPH-5301 in Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IPH-5301 in Lung Cancer Drug Details:IPH-5301 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0317 in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Squamous Cell Carcinoma Drug Details:MP-0317 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tomivosertib Hydrochloride in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tomivosertib Hydrochloride in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tomivosertib Hydrochloride in Metastatic Breast Cancer Drug Details:Tomivosertib hydrochloride (eFT-508) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HPN-328 in Small-Cell Lung Cancer Drug Details:HPN-328 is under development for the...